Skip to main content
. 2015 Mar 26;6(14):11794–11805. doi: 10.18632/oncotarget.3649

Figure 7. A hypothetical schematic of the contribution of ERp19 to GC cells via activation of the FAK/paxillin and ERK1/2 pathways.

Figure 7